{"address1": "333 Lakeside Drive", "city": "Foster City", "state": "CA", "zip": "94404", "country": "United States", "phone": "(650) 574-3000", "fax": "(650) 578-9264", "website": "https://www.gilead.com", "industry": "Drug Manufacturers - General", "industryKey": "drug-manufacturers-general", "industryDisp": "Drug Manufacturers - General", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; Marengo Therapeutics; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.", "fullTimeEmployees": 17600, "companyOfficers": [{"maxAge": 1, "name": "Mr. Daniel P.  O'Day", "age": 59, "title": "Chairman & CEO", "yearBorn": 1965, "fiscalYear": 2024, "totalPay": 7137565, "exercisedValue": 0, "unexercisedValue": 30103994}, {"maxAge": 1, "name": "Ms. Diane E. Wilfong", "age": 62, "title": "Interim Corporate Controller, Chief Accounting Officer & Principal Accounting Officer", "yearBorn": 1962, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Jacquie  Ross C.F.A.", "title": "Vice President of Investor Relations", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Jyoti K. Mehra", "age": 47, "title": "Executive Vice President of Human Resources", "yearBorn": 1977, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Linda Slanec Higgins Ph.D.", "age": 62, "title": "Senior Vice President of Research, Innovation & Portfolio", "yearBorn": 1962, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Rudolf  Ertl", "age": 78, "title": "Senior Vice President of Commercial Operations of Australia, Canada, Europe", "yearBorn": 1946, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Flavius  Martin M.D.", "title": "Executive Vice President of Research", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. William J. Grossman M.D., Ph.D.", "age": 54, "title": "Senior Vice President & Therapeutic Area Head of Gilead Oncology", "yearBorn": 1970, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Janet  Dorling", "age": 49, "title": "Senior Vice President of Intercontinental Region & Global Patient Solutions", "yearBorn": 1975, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Bernard M. Fine M.D., Ph.D.", "title": "VP of Oncology & Franchise Head of Early Development", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 5, "boardRisk": 4, "compensationRisk": 3, "shareHolderRightsRisk": 2, "overallRisk": 2, "governanceEpochDate": 1743465600, "compensationAsOfEpochDate": 1735603200, "irWebsite": "http://investors.gilead.com/phoenix.zhtml?c=69964&p=irol-irhome", "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 111.28, "open": 111.01, "dayLow": 110.47, "dayHigh": 112.01, "regularMarketPreviousClose": 111.28, "regularMarketOpen": 111.01, "regularMarketDayLow": 110.47, "regularMarketDayHigh": 112.01, "dividendRate": 3.16, "dividendYield": 2.84, "exDividendDate": 1741910400, "payoutRatio": 8.1053, "fiveYearAvgDividendYield": 3.97, "beta": 0.236, "trailingPE": 294.44736, "forwardPE": 15.059219, "volume": 7438661, "regularMarketVolume": 7438661, "averageVolume": 8765883, "averageVolume10days": 9896060, "averageDailyVolume10Day": 9896060, "bid": 104.54, "ask": 117.24, "bidSize": 1, "askSize": 1, "marketCap": 139485429760, "fiftyTwoWeekLow": 62.07, "fiftyTwoWeekHigh": 119.96, "priceToSalesTrailing12Months": 4.850992, "fiftyDayAverage": 106.406, "twoHundredDayAverage": 88.6946, "trailingAnnualDividendRate": 3.08, "trailingAnnualDividendYield": 0.027677929, "currency": "USD", "tradeable": false, "enterpriseValue": 154252115968, "profitMargins": 0.01669, "floatShares": 1242618754, "sharesOutstanding": 1246630016, "sharesShort": 22340679, "sharesShortPriorMonth": 21162249, "sharesShortPreviousMonthDate": 1739491200, "dateShortInterest": 1741910400, "sharesPercentSharesOut": 0.0179, "heldPercentInsiders": 0.00121, "heldPercentInstitutions": 0.89594, "shortRatio": 2.36, "shortPercentOfFloat": 0.018, "impliedSharesOutstanding": 1246630016, "bookValue": 15.514, "priceToBook": 7.2121954, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1735603200, "earningsQuarterlyGrowth": 0.248, "netIncomeToCommon": 480000000, "trailingEps": 0.38, "forwardEps": 7.43, "lastSplitFactor": "2:1", "lastSplitDate": 1359331200, "enterpriseToRevenue": 5.365, "enterpriseToEbitda": 11.465, "52WeekChange": 0.6087707, "SandP52WeekChange": 0.101756096, "lastDividendValue": 0.79, "lastDividendDate": 1741910400, "quoteType": "EQUITY", "currentPrice": 111.89, "targetHighPrice": 140.0, "targetLowPrice": 82.0, "targetMeanPrice": 111.7088, "targetMedianPrice": 110.0, "recommendationMean": 1.86667, "recommendationKey": "buy", "numberOfAnalystOpinions": 25, "totalCash": 11568000000, "totalCashPerShare": 9.289, "ebitda": 13454000128, "totalDebt": 27321999360, "quickRatio": 1.332, "currentRatio": 1.597, "totalRevenue": 28753999872, "debtToEquity": 141.962, "revenuePerShare": 23.059, "returnOnAssets": 0.110290006, "returnOnEquity": 0.02286, "grossProfits": 22503000064, "freeCashflow": 10130750464, "operatingCashflow": 10828000256, "earningsGrowth": 0.248, "revenueGrowth": 0.064, "grossMargins": 0.78260005, "ebitdaMargins": 0.4679, "operatingMargins": 0.33069, "financialCurrency": "USD", "symbol": "GILD", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "longName": "Gilead Sciences, Inc.", "regularMarketChangePercent": 0.54816735, "regularMarketPrice": 111.89, "marketState": "PREPRE", "corporateActions": [], "postMarketTime": 1743638230, "regularMarketTime": 1743624001, "exchange": "NMS", "messageBoardId": "finmb_29002", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "firstTradeDateMilliseconds": 696090600000, "postMarketChangePercent": -1.68916, "postMarketPrice": 110.0, "postMarketChange": -1.89, "regularMarketChange": 0.6100006, "regularMarketDayRange": "110.47 - 112.01", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 8765883, "fiftyTwoWeekLowChange": 49.82, "fiftyTwoWeekLowChangePercent": 0.80264217, "fiftyTwoWeekRange": "62.07 - 119.96", "fiftyTwoWeekHighChange": -8.07, "fiftyTwoWeekHighChangePercent": -0.067272425, "fiftyTwoWeekChangePercent": 60.87707, "dividendDate": 1743120000, "earningsTimestamp": 1745524800, "earningsTimestampStart": 1745524800, "earningsTimestampEnd": 1745524800, "earningsCallTimestampStart": 1745526600, "earningsCallTimestampEnd": 1745526600, "isEarningsDateEstimate": false, "epsTrailingTwelveMonths": 0.38, "epsForward": 7.43, "epsCurrentYear": 7.95144, "priceEpsCurrentYear": 14.071665, "fiftyDayAverageChange": 5.484001, "fiftyDayAverageChangePercent": 0.05153846, "twoHundredDayAverageChange": 23.195396, "twoHundredDayAverageChangePercent": 0.26151982, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "1.9 - Buy", "cryptoTradeable": false, "hasPrePostMarketData": true, "shortName": "Gilead Sciences, Inc.", "displayName": "Gilead Sciences", "trailingPegRatio": 0.2339}